You are here:

MS in the media - 31 March 2017

Published on

25-31 March 2017

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

Ocrelizumab approved in US for relapsing and progressive MS

The FDA, the US drug regulator, has licensed ocrelizumab (Ocrevus) as a treatment for both relapsing remitting and primary progressive MS - making it the first drug for PPMS.

Source: FDA
Source: MedPage Today
Source: New York Times

MS Trust link: Ocrelizumab (Ocrevus)

Kidney and bladder stone risk

A study has found that people with multiple sclerosis were more likely to develop kidney or bladder stones than a control group of people who don't have MS. This was particularly so in people using intermittent or indwelling catheters.

Source: MS News Today

MS Trust link: MS research updates

ADHD in children of women with MS

A study looked at the risks of attention-deficit/hyperactivity disorder (ADHD) in children whose mother has an inflammatory or autoimmune condition.  The risk of ADHD was higher in children of mothers with MS

Source: MS News Today

MS Trust link: Children, young people and MS

Print this page